Cargando…
Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives
Immune-checkpoint inhibitors have become valuable therapies in the treatment of patients with non-small-cell lung cancer (NSCLC). Recent clinical trials have shown promising results with regard to efficacy and toxicity profiles of these agents compared to cytotoxic chemotherapy. Nivolumab was one of...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533488/ https://www.ncbi.nlm.nih.gov/pubmed/28769573 http://dx.doi.org/10.2147/OTT.S97903 |